YolTech Therapeutics to Present Positive Clinical Data of YOLT-203 for the Treatment of PH1 at the ERA Congress 2025

YolTech Therapeutics, a clinical-stage gene editing company focused on the development of in vivo genome editing therapies, today announced that interim data from an ongoing investigator-initiated clinical study of YOLT-203 will be presented in an oral session at the European Renal Association (ERA) Congress 2025.

YOLT-203 is an investigational CRISPR-based gene-editing therapy designed as a potential one-time treatment to reduce urinary oxalate levels in patients with Primary Hyperoxaluria Type 1 (PH1). The presentation will include safety and early efficacy data from the first-in-human study, based on YolTech’s proprietary Cas12HF gene-editing system.

YOLT-203 received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration in September 2024, recognizing its potential to address critical unmet needs in PH1 treatment.

Title:
“CRISPR-Cas12 Based In Vivo Gene-Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)”

Date & Time:
Jun 5, 2025 | 8:15 AM – 8:45 AM CEST

Location:
Hall E1, Austria Center Vienna, Vienna, Austria

Session:

Game Changers in Genetic Diseases: Gene Therapy

About ERA
The European Renal Association (ERA) Congress is one of the largest and most prestigious nephrology congresses globally，bringing together thousands of nephrologists, researchers, clinicians, and industry experts to explore the latest scientific and clinical advances in kidney health. The congress offers a multidisciplinary platform highlighting breakthrough innovations in renal physiology, genetics, rare diseases, and kidney replacement therapies, helping to shape the future of nephrology and improve patient outcomes worldwide.